{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-006851","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.753927+00:00","generated_at":"2026-05-22T04:16:52.389498+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aclaris reports Q1 net loss $15.1M, cash runway extended to H1 2028; multiple pipeline milestones ahead","bullets":["Q1 net loss $15.1M vs $16.9M YoY; revenue $1.5M vs $2.4M; cash $190.5M as of March 31, 2025.","Cash runway extended through first half of 2028, fully funding preclinical and clinical plans.","Bosakitug Phase 2 in atopic dermatitis to start Q2 2025; seeking partners for respiratory indications.","ATI-2138 Phase 2a AD top line results expected June 2025; ATI-052 IND cleared, Phase 1 starting Q2 2025.","Jesse W. Hall appointed CMO; Sun Pharma injunction lifted, offering potential non-dilutive financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-006851","json":"https://secwatch.observer/filing/0001558370-25-006851.json","markdown":"https://secwatch.observer/filing/0001558370-25-006851.md","text":"https://secwatch.observer/filing/0001558370-25-006851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837025006851/0001558370-25-006851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837025006851/acrs-20250508x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:16:52.389498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}